[1] BRUNETTI L， DESANTIS E R. Treatment of viral myocarditis caused by coxsackievirus B[J]. Am J Health Syst Pharm， 2008，65（2）：132-137.
[2] ELLIS C R， DI SALVO T. Myocarditis：basic and clinical aspects[J]. Cardiol Rev， 2007， 15(4)：170-177.
[3] SHANG Y， ZHANG W L. The clinical observation of astragalus injection combined with interferon-α of treatment on children with viral myocarditis[J]. Chin Mod Doct(中国现代医生)， 2008，46(18)：178.
[4] DI W， FENG J， XU X Q， et al. The clinical observation of intravenous immune globulin combined with interferon-α-1b of treatment on children with viral myocarditis[J]. J Ningxia Med Coll(宁夏医学院学报)， 2008，30（1）：102-104.
[5] DALIENO L， CALABRESE F， TONA F，et al. Sucessful treatment of enterovirus-induced myocarditis with interferon-α[J]. J Heart Lung Transplant，2003， 22（2）：214-217.
[6] KUHL U， PAUSCHINGER M， SCWIMMBECK P L， et al. Interferon-βtreatment eliminates cardiotropic viruses and improves left ventricular function in patients with myocardial persistence of viral genomes and left ventricular dysfunction [J]. Circulation， 2003，107(22)：2793-2798.
[7] KUHL U， SCHULTHEISS H P. Viral myocarditis： diagnosis， aetiology and management[J]. Drugs， 2009， 69(10)： 1287-1302.
[8] NATHAN M， WALSH R， HARDIN J T， et al. Enteroviral sepsis and ischemic cardiomyopathy in a neonate：case report and review of literature[J]. Asaio J， 2008，54(5)：554-555.
[9] FREUND M W， KLEINVELD G， KREDIET T G， et al. Prognosis for neonates with enterrovirus myocarditis[J]. Arch Dis Child Fetal Neonatal ED， 2010，95(3)：206-212.
[10] KAO K L，YEH S L， CHEN C C. Myopericarditis associated with varicella zoster virus infection[J]. Pediatr Cardiol， 2010，31(5)：703-706.
[11] FERNADEZ-RUIZ M， MUNOZ-CODOCEO C， LOPEZ-MEDRANO F， et al. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult：successful treatment with oral valacyclovir[J]. Intern Med， 2008，47(22)：1963-1966.
[12] HU Y F， QI F W. The advancement of immune pathogenesis and immune therapy on viral myocarditis[J].Foreigen Med Sci Pediatr(国外医学：儿科学分册)， 2005，32（1）：4-6.
[13] KLUGMAN D， BERGER J T， SABLE C A， et al. Pediatric patients hospitalized with myocarditis：a multi-institutional analysis[J]. Pediatr Cardiol， 2010，31(2)：222-228.
[14] AMABILE N， FRAISSE A， BOUVENOT J， et al. Outcome of acute fulminant myocarditis in Children[J]. Heart， 2006， 92(9)：1269-1273.
[15] HAQUE A， BHATTI S， SIDDIQUI F J. Intravenous immune globulin for severe acute myocarditis in Children[J]. Indian Pediatr，2009，46(9)：810-811.
[16] ABE S， OKURA Y， HOYANO M， et al. Plasma contentrations of cytokines and neurohumoral factors in a case of fulminant myocarditis sucessfully treated with intravenous immunoglobulin and percutaneous cardiopulmonary support[J]. Circulation J， 2004，68(12)：1223-1226.
[17] CAMARGO P R， OKAY T S， YAMAMOTO L， et al. Myocarditis in children and detection of viruses in myocardial tissue：Implications for immunosuppresssive therapy[J]. Int J Cardiol，2011，148(2)：204-208.
[18] CHEN H， LIU L，YANG M. Corticosteroids for viral myocarditis[J]. Cochrane Database Syst Rev， 2006， 18(4)：CD004471.
[19] HIA C P，YIP W C L， TAI B C， et al. Immunosuppressive therapy in acute myocarditis： an 18 year systematic review[J]. Arch Dis Child， 2004， 89(6)：580-584.
[20] ZHANG Y， ZHU H， HUANG C， et al. Astragaloside Ⅳ exerts antiviral effects against coxsackie virus B3 by upregulating interferon-gamma[J]. J Cardiovasc Pharmacol，2006，47(2)：190-195.
[21] ZHANG Z C， LI S J， YANG Y Z， et al. Effect of astragaloside on cardiomyocyte apoptosis in murine coxsackievirus B3 myocarditis[J]. J Asian Nat Prod Res（亚洲天然产物研究）， 2007，9(2)：145-151.
[22] WANG H， DING Y， ZHOU J， et al. The in vivo antiviral effects of salidroside from Rhodiola rosea L. against coxsackievirus B3[J]. Phytomedicine， 2009， 16(2-3)：146-155.
[23] SONG X， LIU Z， WANG H， et al. QiHong prevents death in coxsackievirus B3 induced murine myocarditis through inhibition of virus attachment and penetration[J]. Exp Biol Med(Maywood)，2007 ，232(11)：1441-1448.
[24] ZHANG Y， ZHU H， YE G， et al. Antiviral effects of sophoridine against coxsackievirus B3 and its pharmacokinetics in rats[J]. Life Sci， 2006，78(17)：1998-2005.
[25] IMAZIO M， TRINCHERO R. Myopericarditis：Etiology， management， and prognosis [J]. Int J Cardiol， 2008， 127(1)：17-26.
[26] TOPKARA V K， DANG N C， BARILI F， et al. Ventricular assist device use for the treatment of acute viral myocarditis[J]. J Thorac Cardiovasc Surg，2006，31(5)：1190-1191.
[27] HETZER R， STILLER B. Technology insight： use of ventricular assist devices in children[J]. Nat Clin Pract Cardiovasc Med， 2006，3(7)：377-386.
[28] LI Y C， GE L S， YANG P L， et al. Carvedilol treatment ameliorates acute coxsackievirus B3-induced myocarditis associated with oxidative stress reduction[J]. Eur J Pharmacol， 2010，604(1-3)：112-116.
[29] YU F， CHEN R， TAKAHASHI T， et al. Candesartan improves myocardial damage in obese mice with viral myocarditis and induces cardiac adiponectin[J]. Int J Cardiol， 2008， 129(3)：414-421.
[30] XIAO J， SHIMADA M， LIU W， et al. Anti-inflammatory effects of eplerenone on viral myocarditis[J]. Eur J Heart Fail， 2009，11(4)：349-353.